Cullinan Therapeutics earnings were -$180.1M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest CGEM earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$49.2M, up 1.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CGEM reported annual earnings of -$168.1M, with 9.3% growth.
Cullinan Therapeutics Earnings Reports & History FAQ
What were Cullinan Therapeutics's earnings last quarter?
On CGEM's earnings call on Invalid Date, Cullinan Therapeutics (NASDAQ: CGEM) reported Q1 2025 earnings per share (EPS) of -$0.74, up 1.33% year over year. Total CGEM earnings for the quarter were -$49.16 million. In the same quarter last year, Cullinan Therapeutics's earnings per share (EPS) was -$0.75.
Is Cullinan Therapeutics profitable or losing money?
As of the last Cullinan Therapeutics earnings report, Cullinan Therapeutics is currently losing money. Cullinan Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$178.74 million, a 35.05% increase year over year.
What was CGEM's earnings growth in the past year?
As of Cullinan Therapeutics's earnings date in Invalid Date, Cullinan Therapeutics's earnings has grown year over year. CGEM earnings in the past year totalled -$180.07 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.